Want to see BIORQ full AI Analyst Report?

Biora Therapeutics (BIORQ) Price & Analysis

1,088 Followers

BIORQ Stock Chart & Stats

$0.12

$0.03(17.65%)

At close: Jan 08 4:00 PM EST

$0.12

$0.03(17.65%)

Day’s Range― - ―

52-Week Range$0.08 - $7.10

Previous CloseN/A

Volume23.93K

Average Volume (3M)9.55K

Market Cap

$452.00

Enterprise Value$54.77

Total Cash (Recent Filing)$3.20M

Total Debt (Recent Filing)$39.65M

Price to Earnings (P/E)―

Beta-1.83

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding4,522,702

10 Day Avg. Volume3,203

30 Day Avg. Volume9,551

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.17

Price to Sales (P/S)573.04

P/FCF Ratio0.57

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPositive results from the BT-600 Phase 1 clinical trial were presented at a major gastroenterology conference, highlighting potential advances in treatment.

Product DevelopmentThe new smaller BioJet device increases payload capacity and ease of administration, potentially expanding its applications and market interest.

Product Safety And EfficacyThe NaviCap device is developing as a safe and effective means to deliver medication directly to the colon, with minimal systemic exposure.

Strategic AlignmentBiora's strategic realignment to focus on the BioJet program aims to expedite results crucial for licensing and partnering discussions with major pharmaceutical companies.

Bears Say

Financial PerformanceBiora reported a third-quarter EPS of ($5.04), missing both the estimate of ($4.20) and the consensus estimate of ($3.85).

BIORQ FAQ

What was Biora Therapeutics’s price range in the past 12 months?

Biora Therapeutics lowest stock price was $0.08 and its highest was $7.10 in the past 12 months.

What is Biora Therapeutics’s market cap?

Biora Therapeutics’s market cap is $452.00.

When is Biora Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Biora Therapeutics’s earnings last quarter?

Currently, no data Available

Is Biora Therapeutics overvalued?

According to Wall Street analysts Biora Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biora Therapeutics pay dividends?

Biora Therapeutics does not currently pay dividends.

What is Biora Therapeutics’s EPS estimate?

Biora Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biora Therapeutics have?

Biora Therapeutics has 4,522,702 shares outstanding.

What happened to Biora Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Biora Therapeutics?

Currently, no hedge funds are holding shares in BIORQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biora Therapeutics

Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1. Targeted Therapeutics Program: This initiative employs an advanced, ingestible smart capsule engineered for the precise administration of medications directly within the gastrointestinal (GI) tract. The aim is to enhance the efficacy of treatments for inflammatory bowel diseases. 2. Systemic Therapeutics Program: Utilizing an orally delivered capsule, this program offers a non-invasive method for delivering biotherapeutics. These are released straight into the intestinal mucosa, facilitating improved absorption into the bloodstream and broader systemic effects, thereby eliminating the need for injections. Additionally, Biora Therapeutics is engaged in creating diagnostic devices. These tools are designed to evaluate the characteristics of the GI tract and identify various digestive conditions, such as small intestine bacterial overgrowth (SIBO), by enabling diagnosis directly where the disease manifests. Established in 2010, the company previously operated under the name Progenity, Inc. It rebranded as Biora Therapeutics, Inc. in April 2022 to underscore its strategic focus on its therapeutic product pipeline. Its headquarters are situated in San Diego, California.